Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib-Reference-Cited by-同舟云学术

Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib

Published:2008-07-17 Issue:2 Volume:88 Page:219-222
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Hacihanefioglu Abdullah,Tarkun Pinar,Gonullu Emel

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-008-0139-7.pdf

Reference16 articles.

1. Zolk O, Schenke C, Sarikas A. The ubiquitin–proteasome system: focus on the heart. Cardiovasc Res. 2006;70:410–21. doi: 10.1016/j.cardiores.2005.12.021 .

2. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature. 2003;426:895–6. doi: 10.1038/nature02263 .

3. Hermann J, Ciechanover A, Lerman LO, Lerman A. The ubiquitin–proteasome system in cardiovascular disease: a hypothesis extended. Cardiovasc Res. 2004;1:11–21. doi: 10.1016/j.cardiores.2003.09.033 .

4. Vink J, Cloos J, Kaspers GJL. Proteasome inhibition as novel treatment strategy in leukemia. Br J Haematol. 2006;134:253–62. doi:10-1111/j.1315-2141.2006.06170.x.

5. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615–22.

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Major cardiovascular events in long-term multiple myeloma survivors: a Korean case–control study (the CAREMM-2105 study);Clinical and Experimental Medicine;2024-06-12

2. Major cardiovascular events in long-term multiple myeloma survivors: A Korean case- control study (The CAREMM-2105 study);2024-04-04

3. Cardiac Adverse Events Associated with Multiple Myeloma Patients Treated with Proteasome Inhibitors;Oncology;2023

4. Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost;International Journal of Molecular Sciences;2022-11-15

5. Ce que le cardiologue doit savoir sur le suivi d'un patient présentant un myélome multiple;Annales de Cardiologie et d'Angéiologie;2022-11